Lenrispodun - Intra-Cellular Therapies
Alternative Names: IC 200214-12; IC-200214; IC200214 phosphate; ITI 214; ITI-002; ITI-12-Cyclo-(S,R) phosphate; ITI-214 phosphate; ITI12-phosphate; ITI200214-phosphate; Lenrispodun phosphateLatest Information Update: 29 Mar 2023
At a glance
- Originator Intra-Cellular Therapies
- Class Aniline compounds; Antihypertensives; Antiparkinsonians; Cyclopentanes; Fluorinated hydrocarbons; Heart failure therapies; Imidazoles; Ketones; Nootropics; Pyrazoles; Pyridines; Small molecules
- Mechanism of Action Adenosine A2B receptor modulators; Type 1 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Parkinson's disease
- Phase I/II Heart failure
- Preclinical Colorectal cancer; Hypertension
- No development reported Cognition disorders
Most Recent Events
- 13 Mar 2023 Phase-II clinical trials in Parkinson's disease (Adjunctive treatment) in USA (PO)
- 01 Mar 2023 Intra-Cellular Therapies plans a phase II trial for Parkinson’s disease in March 2023
- 08 Apr 2022 Pharmacodynamics data from preclinical trials in Breast cancer presented at American Association for Cancer Research (AACR-2022)